Capricor just reported strongly positive Phase 3 HOPE-3 data in Duchenne muscular dystrophy, driving the stock from a 4.30 low on 2025-11-25 to a 40.37 high on 2025-12-03 and validating a high‑value rare disease asset that investors are still digesting. Technically, despite today’s pullback to 26.47, CAPR remains extremely extended versus its 10-day SMA of 7.9959999999999996 and EMA(9) of 10.5911605758890985, with a sky‑high RSI of 92.9346129332189 and MACD histogram of 1.6441594870337952 in a bullish_momentum state, indicating a powerful but volatile uptrend where sharp dips can be bought for continuation. Short interest is elevated with 14,153,661 shares short, 7.9 days to cover, and short‑volume ratios above 55% on very heavy volume, while the squeeze_score_0_100 of 70 highlights ongoing short positioning that can fuel further spikes on any follow‑up news or partnering chatter. Over a one‑week window, a rebound toward the prior 40.37 high is not base‑case but a retrace into the mid‑30s is plausible given the combination of fresh Phase 3 success, heavy volume, aggressive momentum readings, and the need for shorts to reassess risk, which supports a tactical long with a wide but defined stop below 22.50.

Entry range and stop are internally consistent and feasible vs snapshot quote. Material risks: very high intraday volatility (ATR ~15% of price), extreme momentum/extension after an outsized catalyst, and elevated short interest/days-to-cover creating unpredictable squeeze dynamics. Bid/ask sizes in the snapshot are small relative to headline volume, suggesting potential execution slippage on larger orders. Stop is ~1 ATR below entry (tight relative to this name's recent explosive moves).